Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold Atkins(University of Ottawa), Mark S. Freedman(University of Ottawa), Lisa A.S. Walker(University of Ottawa), Tim Ramsay(University of Ottawa), Christopher Bredeson, Lisa Martin(Canadian Blood Services), Grizel Anstee(Ottawa Hospital), Isabelle Bence‐Bruckler(University of Ottawa), Yves Lapierre, Sheryl McDiarmid(Ottawa Hospital), Linda Hamelin(Ottawa Hospital), Brian Hutton(Ottawa Hospital), Dean Fergusson(Ottawa Hospital), Douglas L. Arnold(McGill University), Mitchell Sabloff(University of Ottawa), Lothar Huebsch(University of Ottawa), Paul Birch(Canadian Blood Services), Amit Bar‐Or(University of Pennsylvania), Hyunwoo Lee(Princess Alexandra Hospital), Paul O’Connor(Augusta University), Jacqueline Chen(Montreal Neurological Institute and Hospital), David Allan(University of Ottawa), Marjorie A. Bowman(United States Department of Veterans Affairs), Mike Halpenny(Canadian Blood Services), Pierre Laneuville(McGill University Health Centre)
Cited by 327
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k